Walleye Capital
PBYI icon

Walleye Capital’s Puma Biotechnology PBYI Stock Holding History

Walleye Capital’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-27,000
Closed -$343K – 2167
2019
Q2 		$343K Buy
+27,000
New +$622K 0.04% 671

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Walleye Capital's PBYI Position: Q2 2025 in Review

Walleye Capital sold out of Puma Biotechnology (PBYI) in Q2 2025, closing a stake of 13,055 shares — an estimated $38.6K sold.

Walleye Capital first reported a position in PBYI in Q3 2018 and held it in 11 quarters. The position peaked at $1.23M in Q4 2021. 121 funds tracked by Wall St. Rank hold PBYI as of Q2 2025.

  • Walleye Capital reported no remaining Puma Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 13,055 Puma Biotechnology shares in Q2 2025, an estimated $38.6K.
  • Walleye Capital first reported a position in Puma Biotechnology in Q3 2018 and held it in 11 quarters.
  • Walleye Capital's Puma Biotechnology position peaked at $1.23M in Q4 2021.
  • 121 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.